APOE ε4 gene variant accelerates age-related Alzheimer blood biomarker changes

A single inherited letter in the genome may help determine when the earliest molecular signs of Alzheimer’s disease begin to appear in the blood. A new study published in Nature Communications analyzed plasma biomarkers in 5,913 participants from the Netherlands Twin Register, aged 30 to 80, and found that carriers of the APOE ε4 variant — the strongest common genetic risk factor for late-onset Alzheimer’s disease — experienced steeper age-related changes in key biomarker concentrations than non-carriers. The findings, based on measurements of phosphorylated tau 217, amyloid-beta 42/40, neurofilament light, and glial fibrillary acidic protein, suggest that genetic status shapes not just whether Alzheimer’s pathology develops, but when its molecular traces become detectable in a simple blood draw.

The research team, led by Rebecca Z. Rousset and Charlotte E. Teunissen of Amsterdam UMC, set out to answer a question that has practical consequences for the growing field of blood-based Alzheimer’s diagnostics: how do genetic risk factors, age, and sex interact to influence the concentrations of plasma biomarkers that clinicians increasingly rely on? Plasma biomarkers are attractive because they are far less invasive and less costly than positron emission tomography scans or cerebrospinal fluid analysis, yet their interpretation depends on understanding how factors such as age and genetics shift baseline values across the population. Without that context, a single biomarker reading could be misleading.

The cohort included 64.1 percent women and 29.8 percent APOE ε4 carriers, a proportion consistent with the general population. The APOE gene comes in three common variants — ε2, ε3, and ε4 — and carrying one or two copies of ε4 substantially raises lifetime risk of Alzheimer’s disease while lowering the age of onset. Beyond APOE, the researchers also computed a polygenic risk score for Alzheimer’s disease that excluded the APOE region, combining hundreds of smaller genetic effects scattered across the genome into a single numerical estimate of inherited risk. This allowed the team to separate the outsized influence of APOE ε4 from the cumulative, subtler contributions of the rest of the genome.

The results were striking in their specificity. Among ε4 carriers, the ratio of amyloid-beta 42 to amyloid-beta 40 — a marker that falls as amyloid plaques accumulate in the brain — began declining more steeply after age 50 compared with non-carriers. Concentrations of p-tau217, a phosphorylated form of the tau protein that is currently among the most accurate blood markers of Alzheimer’s pathology, started rising faster after age 55 in carriers. GFAP, a protein released by astrocytes when they respond to amyloid-driven injury, accelerated upward after age 60 in the carrier group. Each biomarker had its own age threshold, painting a picture of a genetically determined timeline in which amyloid changes precede tau and glial activation changes.

Perhaps the most consequential negative finding involved the polygenic risk score. Unlike APOE ε4, the PRS for Alzheimer’s disease excluding APOE showed no association with biomarker concentrations across age. In other words, hundreds of small genetic variants that collectively raise Alzheimer’s risk did not measurably shift the trajectory of plasma biomarkers in this population-based sample. This dissociation implies that APOE ε4 occupies a unique mechanistic position: its effect on biomarker aging is large enough to detect in a general population, while the polygenic background appears to influence risk through pathways that do not leave the same measurable fingerprint in peripheral blood.

Sex, by contrast, did enter the picture as a factor worth accounting for. With nearly two-thirds of the cohort being female, the dataset had adequate power to evaluate sex differences in biomarker trajectories, and the authors treated sex as an interacting variable in their models. The study’s design — a population-based cohort rather than a clinic-based sample — matters here, because it captures the full spectrum of brain health from cognitively healthy young adults to older individuals with undetected pathology, avoiding the referral biases that complicate interpretation in patient cohorts.

To verify that the cross-sectional age trends they observed actually reflected progressive disease biology rather than cohort artifacts, the team turned to a separate longitudinal resource: the EMIF-AD cohort. In this independent dataset with repeated measurements over time, rising p-tau217 concentrations in ε4 carriers were confirmed to reflect genuine Alzheimer’s pathology rather than nonspecific aging. This confirmation is critical, because p-tau217 has emerged as the leading candidate for blood-based Alzheimer’s screening, and its trajectory in genetically at-risk individuals defines the window in which intervention could begin before symptoms appear.

The technical underpinnings of the study reflect the state of the art in plasma neurochemistry. p-tau217 is measured using ultrasensitive immunoassays capable of detecting femtomolar concentrations, and its specificity for Alzheimer’s-type tau pathology has been validated against amyloid and tau PET imaging in multiple prior studies. The amyloid-beta 42/40 ratio captures the shift in amyloid peptide production that accompanies plaque deposition, while NfL serves as a nonspecific marker of axonal damage and GFAP indexes reactive astrogliosis — the brain’s inflammatory response that often begins years before clinical symptoms. Together, these four analytes form a layered view of Alzheimer’s biology, from amyloid accumulation through glial activation to neurodegeneration.

The age thresholds identified — 50 for amyloid ratio decline, 55 for p-tau217 acceleration, and 60 for GFAP rise in ε4 carriers — carry direct implications for screening strategy. If blood tests for Alzheimer’s are to be deployed preventively, the results suggest that ε4 carriers may benefit from earlier and more frequent testing, with p-tau217 offering the clearest signal of preclinical pathology. For non-carriers, the same biomarkers change more gradually with age, meaning that a single threshold value applied uniformly across the population could miss early disease in some individuals while overdiagnosing it in others. Genetically informed reference ranges could therefore sharpen the accuracy of population screening.

The study also demonstrates the value of twin register resources for disentangling genetic and environmental contributions to brain aging. The Netherlands Twin Register, with its decades-long collection of biological samples and health data, provided the statistical power to model interactions between genotype, age, and sex across a wide age range in a single harmonized dataset. As plasma biomarkers move from research laboratories toward clinical deployment, studies of this scale — grounded in population-based sampling, ultrasensitive assays, and longitudinal validation — will define how these tests are interpreted, who gets tested, and when the molecular countdown of Alzheimer’s disease first becomes visible in a vial of blood.

Subject of Research: APOE ε4 carriership status enhances age-related changes in Alzheimer’s disease plasma biomarkers concentrations

Article Title: APOE ε4 carriership status enhances age-related changes in Alzheimer’s disease plasma biomarkers concentrations

Article References: Rousset, R. Z., den Braber, A., Bongers, B., Boonkamp, L., Wilson, D., Ligthart, L., Pool, R., Visser, P. J., van der Landen, S. M., de Geus, E., & Teunissen, C. E. (2026). APOE ε4 carriership status enhances age-related changes in Alzheimer’s disease plasma biomarkers concentrations. Nature Communications. https://doi.org/10.1038/s41467-026-78723-2

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78723-2

Keywords: APOE, carriership, status, enhances, age-related, changes, Alzheimer, disease, plasma, biomarkers, concentrations, scientific research